GLPBio

Signaling Pathways

Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers

Read More about this category

The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.

ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.

The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.

References:

[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.

[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.

Research Areas

Products Related to Signaling Pathways(39732)

  • GC81337 structure
    GC81337MR24 TFA
    Purity: >99.00%

    MR24 TFA, a G-5555 derivative, is a mammalian STE20-like ( MST ) kinase inhibitor.

  • GC81338 structure
    GC81338BCN512
    CAS: 346691-54-1
    Purity: >99.50%

    BCN512 is an inhibitor of SFRP1 that can inhibit tissue fibrosis.

  • GC81339 structure
    GC81339Taladegib hydrochloride
    CAS: 1258861-21-0
    Purity: >97.00%

    Taladegib (LY2940680) hydrochloride is a Smoothened ( SMO ) antagonist.

  • GC81340 structure
    GC81340WAY-362692
    CAS: 915763-27-8
    Purity: >99.50%

    WAY-362692 is a secreted frizzled-related protein ( sFRP-1 ) inhibitor ( IC 50 of 0.02 μM), targeting the netrin domain of sFRP-1.

  • GC81341 structure
    GC81341IKVAVC acetate
    Purity: >98.00%

    IKVAVC acetate is a derivative peptide of IKVAV with an artificially added cysteine (Cys) at its C-terminus.

  • GC81342 structure
    GC81342CMF9
    Purity: >98.50%

    CMF9, a cyclic peptide molecule, is an inhibitor of the SMAD2-SMAD4 interaction.

  • GC81344 structure
    GC81344Remigromig
    CAS: 3059389-31-7
    Purity: >95.00%

    Remigromig (EYE-103; MK-3000) is a humanized dual-target monoclonal antibody that targets LRP5 and FZD4.

  • GC81345 structure
    GC81345Evabosmig
    CAS: 3061142-96-6
    Purity: >97.50%

    Evabosmig (AGA2118) is a humanized bispecific monoclonal antibody targeting sclerostin ( SOST/sclerostin ) and DKK1.

  • GC81346 structure
    GC81346SNX3-IN-1
    CAS: 2344793-72-0
    Purity: >98.00%

    SNX3-IN-1 is a sorting nexin 3 (SNX3) inhibitor.

  • GC81347 structure
    GC81347YAP/TEAD-IN-2
    CAS: 2957895-40-6
    Purity: >95.00%

    YAP/TEAD-IN-2 (Compound T-1) is a YAP/TEAD inhibitor.

  • GC81348 structure
    GC81348SLD1121
    CAS: 2759011-75-9
    Purity: >99.50%

    SLD1121 is an agonist of the Wnt/β-catenin signaling pathway that enhances Wnt signaling by targeting LRP6 ( K d: 4.52-7.49 nM).

  • GC81349 structure
    GC81349(R,S)-YAP-TEAD-IN-2
    Purity: >98.00%

    (R,S)-YAP-TEAD-IN-2 is the racemic mixture of YAP-TEAD-IN-2.

  • GC81350 structure
    GC81350THR-123 TFA
    Purity: >99.50%

    THR-123 TFA is an orally active ALK3 peptide agonist.

  • GC81351 structure
    GC81351Endotrophin (Mus musculus) TFA
    Purity: >96.50%

    Endotrophin (Mus musculus) TFA is an adipokine, a cleavage fragment derived from Collagen VI, whose levels are elevated in adipose tissue and breast tumors of obese mice.

  • GC81352 structure
    GC81352Anti-ALK7 Antibody
    Purity: >97.50%

    Anti-ALK7 Antibody is a monoclonal antibody that targets ALK7.

  • GC81353 structure
    GC81353PF-07868489
    Purity: >99.00%

    PF-07868489 is a recombinant monoclonal antibody targeting GDF2/BMP-9.

  • GC81354 structure
    GC81354Androgen receptor ligand 4
    CAS: 92071-89-1
    Purity: >96.50%

    Androgen receptor ligand 4 (Compound MDG486) is an androgen receptor ligand with an IC 50 of >100 µM.

  • GC81355 structure
    GC81355JZY3221
    Purity: >98.00%

    JZY3221 is an androgen receptor ( AR ) inhibitor.

  • GC81356 structure
    GC81356Bisphenol F bis(2-chloro-1-propanol) ether
    CAS: 374772-79-9
    Purity: >98.00%

    Bisphenol F bis(2-chloro-1-propanol) ether (BFDGE·2HCl) is an androgen receptor antagonist with a human IC 50 of 18 μM.

  • GC81357 structure
    GC81357JZY3032
    Purity: >98.00%

    JYZ3032 is an orally active super inhibitor of androgen receptor ( AR ) and p300/CBP.

  • GC81358 structure
    GC81358ZN-c5 hydrochloride
    CAS: 2641839-07-6
    Purity: >98.00%

    ZN-c5 hydrochloride is a selective and orally active estrogen receptor degrader.

  • GC81359 structure
    GC81359hFSH-β-(33-53)
    CAS: 142154-55-0
    Purity: >98.50%

    hFSH-β-(33-53) is a polypeptide corresponding to residues 33-53 of hFSH-β, and also a follicle-stimulating hormone ( FSH ) antagonist.

  • GC81360 structure
    GC81360RU 56279
    CAS: 143782-20-1
    Purity: >98.00%

    RU 56279 is an androgen receptor ( AR ) antagonist with strong and systemic anti-androgenic activity.

  • GC81361 structure
    GC81361Medrogestone
    CAS: 977-79-7
    Purity: >98.00%

    Medrogestone is an orally active Progestin.